Veterinary Cannabis Advocacy Gains Momentum with Dr. Katherine Kramer Joining True Leaf

The pet care industry is witnessing a significant shift with the increasing acceptance of plant-derived therapies, and True Leaf is strategically positioning itself as a frontrunner in this evolving landscape. This innovative brand, known for its focus on botanical solutions, has consistently championed the integration of cannabinoid medicine into mainstream wellness. Through its two primary divisions, True Leaf Medicine Inc. and True Leaf Pet Inc., the company offers comprehensive in-house care and cultivates cannabis to provide hemp-based products to both animal and human patients globally. A recent and notable addition to their expert team is Dr. Katherine Kramer, a highly respected veterinarian and Medical Director at the VCA-Canada Vancouver Animal Wellness Hospital.
Dr. Kramer has long been a vocal proponent of incorporating cannabis into veterinary practice. Her journey began early in her career, inspired by numerous instances where she observed the successful synergy of herbal remedies and acupuncture with conventional Western veterinary medicine, advocating for a more holistic and natural approach to animal care. She has been at the forefront of researching and promoting the therapeutic applications of cannabis for animals, driven by a deep commitment to exploring innovative solutions for pet well-being.
In her new role at True Leaf, Dr. Kramer will play a pivotal part in shaping the company's emerging line of medicinal cannabis products tailored for pets. Her extensive knowledge and practical experience in the safe administration, appropriate dosage, and demonstrated effectiveness of medicinal cannabis in animals will be invaluable. This new range of cannabidiol (CBD) products is slated for a 2019 launch within the veterinary market, accompanied by comprehensive educational programs designed to inform both veterinarians and pet guardians on the proper use of these products.
Beyond product development, Dr. Kramer is actively involved with the Canadian Association of Veterinary Cannabinoid Medicine (CAVCM). Through this association, she is working diligently to advocate for amendments to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The ultimate goal of these efforts is to achieve a future classification of CBD as a Veterinary Health Product. Such a reclassification would be transformative, paving the way for True Leaf to introduce legally compliant, safe, and rigorously quality-controlled CBD products to the Canadian pet market, thereby expanding therapeutic options for countless animals.
True Leaf's strategic partnership with Dr. Kramer underscores its commitment to pioneering advanced, plant-based health solutions for animals. This collaboration is set to accelerate the acceptance and accessibility of cannabis-derived treatments, promising a future where pet wellness is enhanced through integrated and natural care approaches.